Bonafide Pricing History, Legitimacy, and What Women Should Know Before Buying

What Is Bonafide and Who Is It For?

Bonafide (formerly Millennial Health) markets a suite of non-hormonal, over-the-counter supplements aimed at women in perimenopause and postmenopause. The brand positions itself as a science-forward alternative to hormone therapy for women who cannot use, or choose not to use, estrogen-based treatments. Products cover hot flashes, vaginal dryness, sleep, libido, and cognitive symptoms.

The intended user is a woman in midlife, typically between 45 and 60, who is experiencing the vasomotor and genitourinary symptoms that accompany falling estrogen. That is not a trivial market: approximately 1.3 million women in the United States enter menopause each year, and the majority will experience hot flashes, with a meaningful subset seeking non-hormonal options.

Is Bonafide the Same as a Pharmaceutical Company?

No. Bonafide sells dietary supplements, not drugs. That distinction matters enormously for how you evaluate its claims.

Under 21 CFR Part 101 and the Dietary Supplement Health and Education Act of 1994 (DSHEA), supplement manufacturers are not required to prove efficacy or safety to the FDA before going to market. The FDA can act against a supplement only after it is already sold and a problem is identified. Bonafide's products carry standard structure/function claims ("supports hormonal balance"), not disease treatment claims, which keeps them within legal bounds but also means independent clinical scrutiny is your primary protection as a consumer.

Life Stage Relevance

Bonafide is designed for perimenopausal and postmenopausal women. If you are in your reproductive years and experiencing cycle irregularities, the root cause and the appropriate treatment are almost certainly different from what these supplements address. Women who are still menstruating, trying to conceive, or who are pregnant should not be shopping for menopause symptom relief in the first place without a clinical evaluation, because those symptoms may signal something treatable and distinct.

Bonafide Pricing History and Trajectory

Prices have moved considerably since the brand launched, and the subscription model has become increasingly central to how costs are structured.

2017 to 2019: Launch Pricing

Bonafide launched with Relizen, a Swedish pollen extract (Sérélys/purified pollen extract marketed in Europe as Femal) repurposed for the U.S. Market. At launch, Relizen retailed for approximately $40 to $45 per month. The brand relied almost entirely on direct website sales and email marketing, with no major retail distribution.

2019 to 2022: Subscription Lock-In and Price Increases

Between 2019 and 2022, Bonafide expanded its product line aggressively, adding Ristela (for libido and sexual function), Clairvee (vaginal microbiome support), Serenol (mood and irritability), and several additional SKUs. Each product launched at a price point between $35 and $60 per month.

During this period the brand moved toward a subscription-first model, offering 20-25% discounts for auto-ship enrollment. One-time purchase prices rose to the $55 to $65 range for flagship products. This subscription architecture is a well-documented revenue strategy in the D2C supplement space: it improves lifetime customer value metrics but also generates cancellation friction, which has been a recurring theme in customer complaints (see the Complaints section below).

2022 to 2025: Current Pricing and Bundling

By 2025, Relizen lists at approximately $60 per one-time purchase and roughly $48 per month on a subscription. Ristela runs similarly. Bundled "systems" that combine two or three products push monthly spend to $90 to $130 for subscribers and substantially more for one-time buyers.

To give you a structured way to think about total cost over time, consider this framework. A woman who starts a Bonafide subscription at perimenopause onset (average age 47) and continues through the first two postmenopausal years (average menopause age 51 in the U.S.) would spend approximately $1,150 to $2,750 total on a single-product subscription, or $2,600 to $6,200 on a two-product bundle, at 2025 pricing, with no guarantee of clinical benefit. That cumulative cost framing is rarely surfaced in brand marketing, and it reframes the per-month price in a way most subscription pages intentionally obscure.

How Does This Compare to Hormone Therapy Costs?

For context, generic oral estradiol (0.5 mg to 1 mg daily) typically costs $10 to $30 per month at retail pharmacies, and many insurance plans cover it. The 2023 Menopause Society position statement on hormone therapy considers MHT the most effective treatment for vasomotor symptoms in women without contraindications. Women who are avoiding hormones for medical reasons, or personal preference, may find non-hormonal alternatives worthwhile. Women who simply assume hormones are unsafe for them based on older data may be making a cost-benefit trade-off based on outdated information.

Is Bonafide Legit? An Evidence Review by Product

The legitimacy question has two layers: is it a real company operating lawfully, and do its products actually work? The answer to the first is yes; the answer to the second is "it depends on which product."

Relizen (Purified Pollen Extract)

Relizen's active ingredient is a non-estrogenic pollen extract (Sérélys) first studied in Scandinavia. A 2005 randomized controlled trial published in Gynecological Endocrinology found that purified pollen extract significantly reduced hot flash frequency compared with placebo over 12 weeks, with a mean reduction in hot flash score of 30% in the active group versus 16% in placebo. A 2007 follow-up study in the journal Climacteric replicated the direction of effect. These trials are small (under 200 participants each), conducted in European populations, and not independently replicated in large U.S. Cohorts. The effect size is modest and the mechanism is not fully understood.

The 2023 Menopause Society nonhormonal therapy position statement lists pollen extract as having some supportive evidence but rates its overall evidence level as low to moderate. That is an honest summary: there is something there, but it is not as strong as the brand's marketing implies.

Ristela (French Maritime Pine Bark / Pycnogenol)

Ristela is primarily marketed for sexual function and libido. Its main ingredient is Pycnogenol (French maritime pine bark extract). A 2013 study in the Journal of Sexual Medicine found improvements in sexual function scores in postmenopausal women, but the sample size was 83 participants and the study was funded by the Pycnogenol manufacturer. Investigator-independent replication in large samples does not exist as of this writing. Women should weigh that funding conflict carefully.

Hypoactive sexual desire disorder (HSDD) in perimenopausal and postmenopausal women is a genuine clinical condition affecting an estimated 40% of women at some point in menopause. It deserves real clinical attention. Ristela may offer a modest signal, but it is not a substitute for evaluation by a clinician who can assess testosterone levels, relationship factors, pain (genitourinary syndrome of menopause is frequently the actual driver), and evidence-based options including ospemifene or local estrogen for GSM.

Clairvee (Vaginal Microbiome Support)

Clairvee targets the vaginal microbiome shift that occurs with estrogen loss in perimenopause and postmenopause. The estrogen decline reduces Lactobacillus dominance and raises vaginal pH, contributing to genitourinary syndrome of menopause (GSM). ACOG Practice Bulletin 141 on menopause and the 2023 Menopause Society GSM position both note that local vaginal estrogen remains the most effective treatment for GSM.

Lactobacillus-based probiotic and prebiotic products for the vaginal microbiome are an active research area but lack the volume of RCT data that would allow confident efficacy claims. Clairvee's ingredient evidence is largely extrapolated from general vaginal probiotic literature rather than from product-specific trials. Women with bothersome GSM symptoms should discuss local vaginal estrogen (safe even in women who cannot use systemic hormones for most indications) with their clinician before spending money on a probiotic.

Serenol (Rye Grass Pollen Extract)

Serenol is marketed for mood and irritability. Its core ingredient is a rye grass pollen extract. The evidence base is thinner than Relizen's. A small Swedish trial (Elia & Mares, 2009, Climacteric) showed some mood benefit, but sample sizes were under 70 participants and the data have not been replicated in larger independent trials. If perimenopausal mood symptoms are significantly affecting your functioning, a clinician can assess for clinical depression (which peaks in perimenopause), sleep disruption as the primary driver, or hormone fluctuation, each requiring different management.

Bonafide Complaints: What the Record Shows

Better Business Bureau Profile

As of mid-2025, Bonafide is not BBB-accredited. The BBB profile for Bonafide Health LLC carries complaints primarily in two categories: difficulty canceling subscriptions and unexpected charges after cancellation requests. Several reviewers describe being charged for additional shipments after requesting cancellation via the website's contact form, with reports of needing to call customer service or dispute charges through their bank.

This is not unique to Bonafide. The FTC has moved against multiple supplement D2C brands for what it terms "negative option" subscription practices, and the FTC's 2023 update to the Negative Option Rule imposes stricter cancellation requirements. Bonafide, to its credit, does now display a cancellation option within the customer account portal, but reviews suggest the process can still be opaque for some users.

FDA and LegitScript Status

No FDA warning letters are on public record for Bonafide as of this review. FDA's dietary supplement adverse event database (CFSAN APPEND) does not show a pattern of serious adverse event reports tied to the brand, though under-reporting of supplement adverse events is a well-documented problem across the industry.

LegitScript, which certifies online pharmacies and supplement retailers, does not appear to currently list Bonafide as a certified merchant. That absence is not a red flag on its own (certification is voluntary), but it does mean you do not have a third-party verification layer.

Are the Products Safe?

For most healthy perimenopausal and postmenopausal women, the ingredients in Bonafide's lineup carry low acute risk. Pollen extract products are contraindicated in women with pollen allergies, which Bonafide's labeling does note. None of the main ingredients are known to cause serious drug interactions at label doses, though women taking anticoagulants should note that Pycnogenol has mild antiplatelet properties and should discuss this with their prescriber.

Women with estrogen-receptor-positive breast cancer history should discuss any supplement with their oncologist. Pollen extracts are marketed as non-estrogenic, but the evidence specifically assessing safety in ER-positive cancer survivors is limited.

Pregnancy, Lactation, and Reproductive-Age Considerations

Bonafide's entire product line is designed for the menopause transition and postmenopause. These products are not tested in pregnant or breastfeeding women, and no safety data in pregnancy exists for any Bonafide formulation.

If you are pregnant or think you might be pregnant: do not use these products. Pollen extracts and pine bark extracts have not been evaluated in human pregnancy trials, and the precautionary principle applies. The FDA categorizes dietary supplements as having no established pregnancy safety rating under the current framework.

If you are breastfeeding: pollen extract transfer into breast milk has not been studied. Until data exist, avoidance is appropriate.

If you are in your reproductive years and experiencing symptoms you think might be menopause-related: premature ovarian insufficiency (POI) affects approximately 1% of women under 40 and can cause hot flashes, cycle changes, and elevated FSH, but it has specific implications for fertility and bone health that require medical management, not supplement self-treatment. A serum FSH, estradiol, and AMH panel with a reproductive endocrinologist or OB-GYN is the right first step.

Contraception note: women in perimenopause who still have any possibility of ovulation need to continue effective contraception until 12 months after their final menstrual period (under age 50) or 24 months after final period (some guidelines differ slightly). Bonafide's products are not contraceptives and do not affect ovulation. Do not conflate non-hormonal menopause supplements with contraceptive management.

Who This Is Right For and Who Should Look Elsewhere

Women Who May Find Bonafide Worth Trying

You have already discussed menopause symptom management with a clinician. Hormone therapy is genuinely contraindicated for you (specific personal or family history of hormone-sensitive cancer, uncontrolled cardiovascular risk, or personal informed preference). You have mild to moderate hot flash burden (fewer than 7 per day) and you want to try a non-hormonal option before escalating. You understand you are paying for supplements with modest evidence, not pharmaceutical-grade treatment.

Women Who Should Pause Before Buying

Your hot flashes are severe (more than 7 to 10 per day) or are significantly disrupting sleep. You have not had a basic menopause evaluation, because other treatable causes of your symptoms have not been ruled out. You are in your reproductive years with intact cycles: see a clinician to rule out thyroid disease, POI, or another diagnosis before attributing symptoms to perimenopause. You are already spending substantially on supplements and have not explored whether your insurance covers hormone therapy or FDA-approved non-hormonal prescription options like fezolinetant (Veozah), which received FDA approval for vasomotor symptoms in May 2023 and represents a genuinely novel non-hormonal mechanism (neurokinin 3 receptor antagonism) with phase 3 trial data behind it.

The Honest Trade-Off

Bonafide's products are not fraudulent. They are not likely to harm most healthy postmenopausal women. The evidence behind some products (Relizen especially) is real but modest. The prices have risen to a point where the monthly cost rivals or exceeds that of prescription options that carry considerably stronger evidence. That is not a reason to dismiss supplements entirely; it is a reason to go in with clear eyes and ideally a clinician in the loop.

How to Evaluate Any Supplement Brand: A Practical Checklist

Before spending money on any supplement brand, run through these questions:

• Does the company cite peer-reviewed trials, or only testimonials and structure/function claims?
• Are the cited trials product-specific, or are they on a generic ingredient that a competitor also uses?
• Who funded the cited trials?
• Does the brand have a process for reporting adverse events to the FDA (as required under 21 CFR Part 111)?
• Is cancellation clearly described before you enter a subscription?
• Has a clinician who knows your full health history been part of the decision?

For women in the menopause transition, the 2023 Menopause Society position statement is the most authoritative and up-to-date evidence synthesis available, and it covers both hormonal and non-hormonal options with graded evidence levels. Reading it, or asking your provider to walk through it with you, is worth more than any amount of brand-website browsing.